OPTIMIZE-1 Primary Analysis: Safety, Efficacy and Biomarker Results of a Phase 1b/2 Study Combining CD40 Agonist Mitazalimab with Mfolfirinox in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac).
Journal of Clinical Oncology（2024）
Key words
Metastatic Pancreatic Cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined